Eleven (NASDAQ: EBIO), founded in 2008, is a publicly-traded late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on its Targeted Protein Therapeutics (TPTs) platform. The company raised a $50M IPO in 2014 and changed its name to Sesen Bio in 2018.
Latest Press from Eleven Biosciences
- Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis 10.15.2015
- Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results 08.13.2015
- Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics 02.17.2010